Deep Visual Proteomics maps proteotoxicity in a genetic liver disease.

Journal: Nature
Published Date:

Abstract

Protein misfolding diseases, including α1-antitrypsin deficiency (AATD), pose substantial health challenges, with their cellular progression still poorly understood. We use spatial proteomics by mass spectrometry and machine learning to map AATD in human liver tissue. Combining Deep Visual Proteomics (DVP) with single-cell analysis, we probe intact patient biopsies to resolve molecular events during hepatocyte stress in pseudotime across fibrosis stages. We achieve proteome depth of up to 4,300 proteins from one-third of a single cell in formalin-fixed, paraffin-embedded tissue. This dataset reveals a potentially clinically actionable peroxisomal upregulation that precedes the canonical unfolded protein response. Our single-cell proteomics data show α1-antitrypsin accumulation is largely cell-intrinsic, with minimal stress propagation between hepatocytes. We integrated proteomic data with artificial intelligence-guided image-based phenotyping across several disease stages, revealing a late-stage hepatocyte phenotype characterized by globular protein aggregates and distinct proteomic signatures, notably including elevated TNFSF10 (also known as TRAIL) amounts. This phenotype may represent a critical disease progression stage. Our study offers new insights into AATD pathogenesis and introduces a powerful methodology for high-resolution, in situ proteomic analysis of complex tissues. This approach holds potential to unravel molecular mechanisms in various protein misfolding disorders, setting a new standard for understanding disease progression at the single-cell level in human tissue.

Authors

  • Florian A Rosenberger
    Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany. rosenberger@biochem.mpg.de.
  • Sophia C Mädler
    Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany.
  • Katrine Holtz Thorhauge
    Department of Gastroenterology and Hepatology, Centre for Liver Research, Odense, Denmark.
  • Sophia Steigerwald
    Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany.
  • Malin Fromme
    Medical Clinic III, Gastroenterology, Metabolic Diseases and Intensive Care, University Hospital RWTH, AachenHealth Care Provider of the European Reference Network on Rare Liver Disorders (ERN RARE LIVER), Aachen, Germany.
  • Mikhail Lebedev
    Department of Neurobiology and Duke University Center for Neuroengineering, Duke University, Durham, NC 27710, U.S.A.; and Center for Bioelectric Interfaces of the Institute for Cognitive Neuroscience of the National Research University Higher School of Economics, Moscow, Russia; and Department of Information and Internet Technologies of Digital Health Institute, I.M. Sechenov First Moscow State Medical University, Moscow, Russia mikhail.a.lebedev@gmail.com.
  • Caroline A M Weiss
    Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany.
  • Marc Oeller
    Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany.
  • Maria Wahle
    Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany.
  • Andreas Metousis
    Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany.
  • Maximilian Zwiebel
    Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany.
  • Niklas A Schmacke
    Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany.
  • Sönke Detlefsen
    Odense PIPAC Center (OPC) and Odense Pancreas Center (OPAC), Department of Pathology, Odense University Hospital, Odense, Denmark.
  • Peter Boor
    Institute of Pathology, University Hospital Aachen, RWTH Aachen University, Aachen, Germany.
  • Ondrej Fabian
    Institute for Clinical and Experimental Medicine, Prague, 140 21, Czechia; Third Faculty of Medicine, Charles University, Prague, 100 00, Czechia.
  • Soňa Fraňková
    Department of Hepatogastroenterology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
  • Aleksander Krag
    Department of Gastroenterology and Hepatology, Odense University Hospital, Odense C, Denmark.
  • Pavel Strnad
    Medical Clinic III, Gastroenterology, Metabolic Diseases and Intensive Care, University Hospital RWTH, AachenHealth Care Provider of the European Reference Network on Rare Liver Disorders (ERN RARE LIVER), Aachen, Germany.
  • Matthias Mann
    From the ‡Proteomics and Signal Transduction Group and mmann@biochem.mpg.de.